With a substantial discount to Catalyst's Firdapse, is Jacobus poised to win physician, payer support for off-label adult LEMS use?

Weeks ago, the FDA endorsed a Lambert-Eaton myasthenic syndrome (LEMS) drug from family-run New Jersey-based company called Jacobus Pharmaceuticals in pediatric patients, on the basis of adult data, to the surprise of Catalyst Pharmaceuticals which only last year got its pricey — yet similar — treatment for the rare autoimmune disorder across the finish line in adults. It has now been revealed that Jacobus’ version carries a price that is less than half of Catalyst’s Firdapse — a move that could fuel off-label prescription in adults.